Table 1 Patient demographics and treatment details
From: Oritavancin as sequential therapy for Gram-positive bloodstream infections
Variable | N = 72 |
|---|---|
Age (years), mean (SD) | 54 (16) |
Male sex, n (%) | 44 (61) |
Race, n (%) | |
White | 46 (64) |
Hispanic | 15 (21) |
Black | 5 (7) |
Body mass index (kg/m2), mean (SD) | 28 (8) |
Charlson Comorbidity Index, median (IQR) | 3 (1–5) |
Index organism(s), n (%) | |
S. aureus | 49 (68) |
Methicillin-resistant | 12 (17) |
Streptococcus spp. | 19 (26) |
Beta-hemolytic | 13 (18) |
Viridans group & other Streptococcus spp.a | 6 (8) |
Enterococcus spp. | 7 (10) |
Vancomycin-resistant | 4 (6) |
Coagulase-negative Staphylococcus spp. | 6 (8) |
Otherb | 4 (6) |
Infectious diseases consult, n (%) | 71 (99) |
Prior antibiotics therapy, n (%) | |
Vancomycin | 64 (89) |
Ceftriaxone | 36 (50) |
Cefazolin | 35 (49) |
Linezolid | 18 (25) |
Ampicillin | 10 (14) |
Ceftaroline | 7 (10) |
Daptomycin | 6 (8) |
Days of antibiotics prior to oritavancin dose, median (IQR) | 11 (5–17) |
Bloodstream infection clearance prior to oritavancin administration c, n (%) | 69 (99) |
Oritavancin dose, n (%) | |
800 mg once | 4 (6) |
1200 mg once | 53 (74) |
1200 mg, followed by 1200 mg | 5 (7) |
1200 mg, followed by 800 mg | 10 (14) |
Hospital LOS, median (IQR) | 17 (8–24) |